Gabriel Pardo
Welcome,         Profile    Billing    Logout  
 0 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pardo, Gabriel
CELLO, NCT04877457: Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.

Terminated
4
3
US
Ocrelizumab, Placebo
Yale University, Genentech, Inc.
Radiologically Isolated Syndrome, Multiple Sclerosis
06/23
06/23
CLOCK-MS, NCT03963375: Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

Active, not recruiting
4
47
US
Cladribine
Washington University School of Medicine, EMD Serono
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
05/25
05/25
NCT05285891: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Recruiting
4
123
US
Ocrelizumab, Ocrevus, Placebo for Ocrelizumab
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence (ACE), Rho Federal Systems Division, Inc., Genentech, Inc.
Multiple Sclerosis
08/28
08/28
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Calendar Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis
Active, not recruiting
3
1882
Europe, Canada, Japan, US, RoW
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/27
09/28
OPTIS, NCT05566769: Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

Recruiting
N/A
103
Europe, US
NMOSDCopilot smartphone application
Ad scientiam
Neuromyelitis Optica
04/25
04/26
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Recruiting
N/A
900
US
Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/25
08/25
MS-DETECT, NCT05816122: Early Detection of Multiple Sclerosis Progression with MSCopilot® Detect

Recruiting
N/A
314
Europe, Canada, US
MSCopilot® Detect mobile application
Ad scientiam
Multiple Sclerosis
12/26
12/26
Freeman, Leorah
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
CAVS-MS, NCT04495556: Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis

Active, not recruiting
N/A
420
Canada, US
MRI
The Cleveland Clinic, National Institute of Neurological Disorders and Stroke (NINDS), University of Pennsylvania, Cedars-Sinai Medical Center, National Institutes of Health (NIH)
Multiple Sclerosis
06/25
06/25
MS-DETECT, NCT05816122: Early Detection of Multiple Sclerosis Progression with MSCopilot® Detect

Recruiting
N/A
314
Europe, Canada, US
MSCopilot® Detect mobile application
Ad scientiam
Multiple Sclerosis
12/26
12/26

Download Options